Ensign Peak Advisors
EDIT icon

Ensign Peak Advisors’s Editas Medicine EDIT Stock Holding History

Ensign Peak Advisors’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-19,360
Closed -$237K – 1913
2022
Q3 		$237K Hold
19,360
– – ﹤0.01% 1802
2022
Q2 		$229K Hold
19,360
– – ﹤0.01% 1751
2022
Q1 		$368K Hold
19,360
– – ﹤0.01% 1679
2021
Q4 		$514K Buy
+19,360
New +$666K ﹤0.01% 1621

Other funds holding EDIT

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Ensign Peak Advisors's EDIT Position: Q4 2022 in Review

Ensign Peak Advisors sold out of Editas Medicine (EDIT) in Q4 2022, closing a stake of 19,360 shares — an estimated $237K sold.

Ensign Peak Advisors first reported a position in EDIT in Q4 2021 and held it in 4 quarters. The position peaked at $514K in Q4 2021. 250 funds tracked by Wall St. Rank hold EDIT as of Q4 2022.

  • Ensign Peak Advisors reported no remaining Editas Medicine position as of Q4 2022 after selling out during the quarter.
  • Ensign Peak Advisors sold 19,360 Editas Medicine shares in Q4 2022, an estimated $237K.
  • Ensign Peak Advisors first reported a position in Editas Medicine in Q4 2021 and held it in 4 quarters.
  • Ensign Peak Advisors's Editas Medicine position peaked at $514K in Q4 2021.
  • 250 funds tracked by Wall St. Rank held Editas Medicine as of Q4 2022.

Based on Ensign Peak Advisors's 13F filing for Q4 2022, filed 13 Feb 2023.